A groundbreaking study conducted at the San Carlos Clinical Hospital in Madrid has revealed an innovative, non-hormonal therapy that led to complete hair regrowth in 100% of treated male mice and almost full recovery in 90% of females. The research, led by Dr. Eduardo López Bran, combined adipose-derived stem cells (ASCs) with adenosine triphosphate (ATP), showcasing a promising alternative to conventional hair loss treatments such as finasteride and surgical hair transplants.
Published on June 7, 2025, in Stem Cell Research & Therapy, the study focused on C57BL6-strain mice with dihydrotestosterone (DHT)-induced androgenetic alopecia (AGA)—a well-established model for male pattern baldness. Researchers injected the stem cell-ATP combination into the depilated dorsal area and repeated the procedure after three days. The treated area was monitored at intervals up to day 21 using photographic analysis and skin biopsies.
In male mice, every subject treated with low-dose ASCs plus either liposomal or non-liposomal ATP displayed either full or intense regrowth by day 21. Female mice similarly benefited, though the optimal results were achieved with medium-dose ASCs paired with non-liposomal ATP—producing 90% intense or complete regrowth.
Dr. López Bran highlighted the discovery of a synergistic effect between stem cells and ATP, which enhanced follicle recovery far more than either component alone. He noted, “This synergy favors the recovery of the hair follicle, promoting hair growth.”
Histological analysis supported the visual results, revealing increases in follicular density and bulb size—clear indicators of follicle activation—and confirming the therapy’s regenerative impact.
This stem cell-ATP therapy stands out as a non-hormonal option, distinguishing it from finasteride—a common 5α‑reductase inhibitor with associated side effects like sexual dysfunction and mood disturbances. It also offers a potentially less invasive and costly alternative to hair transplantation, which often demands multiple sessions and carries risks and variability.
The Spanish team’s work fits into a broader scientific context. Previous studies have explored other regenerative strategies, such as using microRNA to “soften” aged follicle stem cells or leveraging senescent cell signaling molecules like osteopontin to reawaken dormant follicles. However, this Madrid study appears to be the first non-genetic, stem-cell-based method demonstrating near-complete regrowth in male subjects—a finding that could have significant translational value.
Despite the compelling animal data, several hurdles remain before this approach can be applied to humans. Researchers acknowledge that dosage, delivery methods, long-term efficacy, and safety must all be thoroughly vetted in clinical trials. The study’s Spanish authors have expressed optimism, suggesting human trials could begin within the next few years—potentially bringing a new treatment option to the millions affected by androgenetic alopecia.
Public enthusiasm for a new, side-effect-free treatment option is high. Hair loss remains a significant concern, not only for its aesthetic implications but also because of how it affects self-esteem and psychological well-being. Traditional treatments, like minoxidil and finasteride, offer modest results but often disappoint patients over time. Surgical hair transplants, while effective for some, come with considerable cost and risk. A successful stem-cell ATP therapy could redefine the standard of care.
Further reinforcing the promise of cellular therapies, the treated mice showed histological improvements indicative of true follicular regeneration—an outcome rarely seen with existing treatments. This suggests the therapy doesn’t just slow hair loss—it may actively reverse follicle miniaturization and stimulate dormant follicles to re-enter growth cycles.
Researchers stress that breakthroughs in mice often face setbacks in human trials. Differences in physiology, immune response, and scalp environment can alter efficacy and safety profiles. Nevertheless, the team at Madrid’s Hospital Clínico San Carlos is moving forward cautiously but confidently, with plans for phase 1 trials that will focus on safety, optimal dosage, and treatment protocols.
In the meantime, other therapeutic innovations continue to evolve. Research into microRNA-205 delivery, exosome injections, platelet-rich plasma (PRP), low-level laser therapy, and even hair cloning shows a vibrant future for regenerative hair science. However, the stem cell–ATP synergy currently stands as one of the most promising non-hormonal approaches under development.
The Madrid team’s results also highlight the value of combining cellular energy boosters (like ATP) with regenerative therapies. While clinical translation is still in progress, the prospect of offering a safer, more effective treatment—one that reduces reliance on hormones or surgery—could have far-reaching implications for public health and men’s well-being.
In conclusion, this novel stem cell and ATP treatment represents a significant leap forward in hair restoration research. Should human trials replicate the robust outcomes seen in mice, this therapy may revolutionize treatment for androgenetic alopecia and offer fresh hope to countless men and women seeking effective, low-risk solutions.